C
CALC
CALCIMEDICA INC
4.33
-0.26-5.66%Closed16:00 12/12 EST
OPEN/PREV CLOSE4.520/4.590
TODAY RANGE4.260-4.590
VOL61.15K
MARKET CAP62.39M
52 WEEK RANGE1.420-4.815
AVG VOL (3M)68.91K
% TURNOVER0.42%
TURNOVER--
P/E (TTM)-2.7057
% RANGE5.88%
EPS(TTM)-1.6003
P/E(FORWARD)-2.6084
P/B-230.3191
BVPS-0.0188
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP47.61M
SHARES OUTSTANDING14.41M
NEXT EARNINGS03/25-03/30
FREE FLOAT11.00M
LOT SIZE1
EX-DATE03/20/2023
News
Press Releases
Financial Reports
Profile
TipRanks·11/17 13:55
Oppenheimer Reaffirms Their Buy Rating on CalciMedica (CALC)
Seeking Alpha·11/12 14:54
CalciMedica GAAP EPS of -$0.52
Reuters·11/12 12:16
CalciMedica Reports Q3 2025 Results and Advances Auxora Clinical Programs
Reuters·11/12 12:15
CalciMedica reports Q3 net loss of $7.8 mln
TipRanks·11/12 12:10
CalciMedica announces publication in JCI preclinical study of CM5480
Dow Jones·11/12 12:06
*CalciMedica 3Q Research and Development Expenses $3.9M >CALC
TipRanks·11/12 12:05
CalciMedica reports Q3 EPS (52c), consensus (41c)
Benzinga·11/12 12:03
CalciMedica Q3 EPS $(0.52) Misses $(0.42) Estimate
Reuters·11/12 12:01
CALCIMEDICA Q3 BASIC EPS USD -0.52
Reuters·11/12 12:01
CALCIMEDICA INC - CASH POSITION EXPECTED TO FUND OPERATIONS INTO 2H 2026
Reuters·11/10 12:03
CalciMedica Reports Auxora Improves Kidney Function in Preclinical AKI Study
TipRanks·11/06 21:39
CalciMedica Boosts Stock Offering to $9.7 Million
TipRanks·10/14 11:10
CalciMedica and Telperian collaborate to integrate AI to Auxora clinical trials
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number : +852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email : service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.